Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy,
and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting
adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance
and/or uncontrolled systolic hypertension.